Add like
Add dislike
Add to saved papers

The long non-coding RNA MALAT1 interacted with miR-218 modulates choriocarcinoma growth by targeting Fbxw8.

Among the first found cancer-related long non-coding RNAs (lncRNAs), MALAT1 is one that involves in the development and progression of some tumors. MALAT1 can be aberrantly expressed in hepatocellular carcinoma, cervical, breast, ovarian cancers, as well as colorectal cancer. The paper aims to make certain the function of MALAT1 in human choriocarcinoma cell lines by investigating the detailed effects and molecular mechanisms. Being specifically upregulated in choriocarcinoma cell lines, the under-researched lncRNA-MALAT1 promoted choriocarcinoma cell growth by targeting miR-218. After MALAT1 knockdown, proliferation of human choriocarcinoma cell in vitro was dramatically hindered, and the tumor size in vivo was reduced. What is more, miR-218-mediated Fbxw8 regulation was required for MALAT1-induced choriocarcinoma cell proliferation. Taken together, MALAT1 might promote choriocarcinoma tumor growth through miR-218-mediated Fbxw8 regulation. According to our data, MALAT1 might be an oncogenic lncRNA that promoted choriocarcinoma proliferation and could be therapeutically targeted in human choriocarcinoma.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app